Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $81.50

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $81.50.

A number of research analysts have recently issued reports on RARE shares. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Morgan Stanley dropped their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, July 14th. Wedbush dropped their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, July 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a report on Friday, August 8th.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $32.02 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $57.99. The firm has a 50-day simple moving average of $29.82 and a 200-day simple moving average of $32.94. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -5.79 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same period in the prior year, the business earned ($1.52) EPS. The firm’s revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Fred Alger Management LLC grew its holdings in Ultragenyx Pharmaceutical by 12.5% during the first quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company’s stock worth $18,997,000 after acquiring an additional 58,372 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in Ultragenyx Pharmaceutical during the second quarter worth $353,000. Assenagon Asset Management S.A. boosted its position in Ultragenyx Pharmaceutical by 439.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock worth $42,314,000 after purchasing an additional 947,865 shares in the last quarter. Millennium Management LLC boosted its position in Ultragenyx Pharmaceutical by 2.2% during the first quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company’s stock worth $25,796,000 after purchasing an additional 15,157 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Ultragenyx Pharmaceutical during the first quarter worth $4,400,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.